Floatz logo

Alectinib

Thyroid Cancer

Hoffmann-La RocheSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

42 Active assets in the Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Kineta Inc.
Phase 2BB
Denosumab
Amgen
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
[68ga]ga-nota-rt4
RenJi Hospital
Phase 2/3CCC
[18f]f-resca-rt4
RenJi Hospital
Phase 2/3CCC

View all 50 →

Same molecule, other indications

Alectinib is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 4
66 / 100
View asset →
anaplastic large cell lymphomaActive
B
Indicative · Phase 2/3
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
B
Indicative · Phase 2/3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →